Clinical Trials

Multiple clinical trials without specified phases evaluate Toluidine Blue O across diagnostic and histological applications. An active, recruiting study sponsored by Insel Gruppe AG University Hospital Bern assesses histological validation and imaging indices for evaluating cartilage damage in hip osteoarthritis, while a completed study sponsored by Cairo University evaluated toluidine blue staining versus frozen sections for surgical margin assessment in oral squamous cell carcinoma. Together, these academic hospital-sponsored studies demonstrate the cationic dye's utility in diagnostic histology, intraoperative margin evaluation, and tissue damage assessment.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06185036 Recruiting
Cartilage Damage|Osteoarthritis Hip
Insel Gruppe AG University Hospital Bern
 2022-09-01 --
NCT03554967 Completed
Oral Squamous Cell Carcinoma
Cairo University
 2018-07-02 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Toluidine Blue O product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a cationic thiazine dye, Toluidine Blue O selectively intercalates into nucleic acids and binds polyanionic glycosaminoglycans, generating reactive oxygen species upon photoactivation that promote oxidative cellular damage and differential cellular uptake. This preferential binding to acidic tissue components and dysplastic cellular structures provides specific histological staining, enabling the precise intraoperative assessment of surgical margins in oral squamous cell carcinoma and the quantitative evaluation of structural lesions in hip cartilage damage and osteoarthritis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.